MedComm · Published 2026-07-01 · DOI 10.1002/mco2.70813
Wisal Sawaed, Ahmad Dallasheh, Sivan Eliyahu, Nura Aburomi, Aviad Sivan, Marina Kurtz, Michael Assa, Assaf Malka, Shira Perez, Ron Piran
ABSTRACT Diabetes encompasses a range of diseases characterized by chronic hyperglycemia and serious health complications. However, predicting therapeutic response in latent autoimmune diabetes in adults (LADA) remains a major challenge, limiting the development of personalized treatment strategies. LADA is a relatively newly defined diabetes type that shares features of Type 1 diabetes (T1D) and Type 2 diabetes and is estimated to be more prevalent than T1D. We developed a LADA model in NOD mice and assessed combination treatment (CT) comprising GABA, sitagliptin, and omeprazole. Surprisingly, ∼30% of the CT‐treated mice completely recovered, exhibiting normoglycemia and insulin independence. We identified two cell‐free RNA markers, Adgrb1 and Chd5, that distinguish responders from nonresponders, indicating promising predictive ability. These discoveries offer a potential diagnostic tool for identifying LADA patients who could benefit from CT, representing an advance in personalized diabetes treatment. CT‐induced β‐cell neogenesis involved replication, providing valuable insights into β‐cell regeneration mechanisms. Furthermore, the cured mice exhibited insulitis primarily populated by T regulatory Type 1 cells, potentially suppressing autoimmunity and facilitating β‐cell survival and regeneration. This study opens new avenues for targeted LADA therapies and paves the way for precision medicine in diabetes management.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Sawaed, W., Dallasheh, A., Eliyahu, S., et al. (2026). Markers Predicting Cure With Combinatorial Treatment in a Mouse Model of Latent Autoimmune Diabetes in Adults. MedComm. https://doi.org/10.1002/mco2.70813